Dr Taub on the Benefits of a Multimodal Treatment Approach in Prostate Cancer

"A multimodal clinic, [which we have at Baptist Health] is exceptionally beneficial for patient care and physician engagement. It's a whole team approach that makes a huge difference in patient care."

David Taub, MD, FACS, urologist and director of urologic oncology and director of urologic robotic surgery at the Eugene M. & Christine E. Lynn Cancer Institute, part of Baptist Health, at Boca Raton Regional Hospital, discussed strategies for navigating therapy selection for prostate cancer patients during Prostate Cancer Awareness Month.

Taub began by emphasizing the importance of a comprehensive approach, particularly in light of the growing number of available treatment options across different disease stages.

A multimodal approach to clinical care, like that employed at Baptist Health, as exceptionally beneficial for both patient care and physician engagement, he stated. This collaborative environment allows specialists to actively discuss optimal treatment paths for individual patients, fostering shared decision-making, Taub said. Patients, in turn, highly appreciate this comprehensive, integrated support system, which provides them with personalized guidance and access to a diverse team of professionals, including nutritional support, social workers, and genetic counselors, he added. This "whole team approach" is crucial for making a significant positive difference in patient care, Taub asserted.

In addition to the team-based care, Taub underscored the increasing significance of genomic testing. He clarified that this goes beyond traditional genetic testing, which identifies inherited risk factors like mutations in the BRCA gene. Instead, genomic testing focuses on analyzing the tumor's specific biology and underlying DNA to assess the risk for disease progression. This advanced understanding of the tumor's genetic makeup plays a vital role in enabling clinicians to personalize patient care, tailoring therapeutic strategies to each patient's unique cancer profile, Taub concluded.